Panacea Biotec share news, announcements and annual reports
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹329.05up ₹9.80 (3.07%)BSE ₹328.10
Share price at the NSE close on 28 Oct 2026. Previous close ₹319.25.
28 Oct: open ₹319.05, high ₹333.55, low ₹317.50
52-week range of traded prices to 28 Oct 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,015 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.41
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,92237.5% delivered
Panacea Biotec disputes and clarifications
34 filed, newest first.
Sep 2026
Jul 2026
Apr 2026
Mar 2026
Dec 2025
Nov 2025
Sep 2025
Jul 2025
9 Jul · Legal
Mar 2025
12 Mar · Legal
The exchange asked on 11 Mar 2025
Dec 2021
2 Dec · Legal
The exchange asked on 1 Dec 2021
Apr 2021
29 Apr · Legal
The exchange asked on 28 Apr 2021
Dec 2020
3 Dec · Legal
The exchange asked on 2 Dec 2020
Apr 2020
29 Apr · Legal
The exchange asked on 28 Apr 2020
9 Apr · Legal
The exchange asked on 8 Apr 2020
Nov 2019
20 Nov · Legal
Exchange has sought clarification from Panacea Biotec Limited with respect to announcement dated 19-Nov-2019, regarding Panacea Biotec announced three key managerial appointments / elevation in its top-level leadership in Sales, Operations and R&D. On basis of above the Company is required to clarify following: 1. Date of appointment. The response of the Company is awaited.
Jan 2018
16 Jan · Legal
The exchange asked on 15 Jan 2018
Sep 2017
14 Sep · Legal
Exchange has sought clarification from Panacea Biotec Limited with respect to announcement dated 13-Sep-2017, regarding " Outcome of Board Meeting held on September 13, 2017.". On basis of above the Company is required to clarify following: 1. Brief details of the division to be demerged;2. Turnover of the demerged division and as percentage to the total turnover of the listed entity in the immediately preceding financial year / based on financials of the last financial year;3. Rationale for demerger;4. Brief details of change in shareholding pattern (if any)of all entities;5. In case of cash consideration amount or otherwise share exchange ratio;6. Whether listing would be sought for the resulting entity;The response of the Company is awaited.
Dec 2014
12 Dec · Legal
Exchange had sought clarification from Panacea Biotec Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "Panacea Biotec through its local entity Panacea Biotec Germany GmbH is proceeding in line with the instructions of the Germany s drug regulator and is taking appropriate steps to overcome the situation. The overall impact of this action on the Company s financials is expected to be immaterial".11 Dec · Legal
Exchange has sought clarification from Panacea Biotec Limited with respect to recent news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.